Premium
Klotho gene‐modified BMSCs showed elevated antifibrotic effects by inhibiting the Wnt/β‐catenin pathway in kidneys after acute injury
Author(s) -
Zhang Feng,
Wan Xin,
Cao YiZhi,
Sun Dong,
Cao ChangChun
Publication year - 2018
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1002/cbin.11068
Subject(s) - klotho , wnt signaling pathway , mesenchymal stem cell , fibrosis , catenin , kidney , stem cell , cancer research , acute kidney injury , medicine , microbiology and biotechnology , biology , endocrinology , signal transduction
Klotho is a protein primarily expressed in renal tubular epithelial cells. Studies have suggested that Klotho is an antiaging protein that reduces renal fibrosis after acute kidney injury (AKI) and inhibits stem cell senescence. Bone marrow mesenchymal stem cells (BMSCs) have consistent proliferation ability and multidirectional differentiation ability and have been used to treat tissue injury. Thus, we hypothesized that Klotho expressed in BMSCs could increase the renal protective effects of BMSCs. To verify the hypothesis, we isolated BMSCs from C57BL/6 mice, transfected them with Klotho‐GFP‐adenovirus and investigated the change in BMSC proliferation. We then transplanted Klotho‐GFP‐BMSCs into mice with AKI and investigated the therapeutic effect compared with that of sham‐treated mice and GFP‐BMSC‐transplanted mice. Kidney fibrosis after ischemia/reperfusion injury (IRI) was relieved by BMSC transplantation, and the antifibrotic effect of BMSCs was significantly enhanced by overexpressing the Klotho gene. Mechanistic studies showed that Klotho increased pluripotency gene expression in BMSCs. Klotho produced by Klotho‐GFP‐BMSCs inhibited the Wnt/β‐catenin pathway in renal tubular epithelial cells (TECs). Klotho‐GFP‐BMSCs showed increased proliferative ability and more potent immuno‐regulation ability than did GFP‐BMSCs. Our findings suggested that Klotho gene‐modified BMSCs may be a better choice for cell therapy after AKI.